Study analysis · Nature reviews. Endocrinology · 2026
1 in 8 pregnant women have a hidden condition that puts their baby at risk—and most doctors don't screen for it.
One in eight pregnant women have PMOS, a metabolic disorder that makes pregnancy riskier, but new guidelines say they should get extra care to stay safe.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This article is like a story that pulls together other people's research about a health condition, but it doesn't do any new experiments or check how good those other studies were. So it can tell you what people think might be linked, but it can't prove that one thing causes another.
What’s the bottom line?
Some women have a condition called PMOS that makes their bodies handle sugar and hormones differently, which can cause problems during pregnancy.
How strong is this study?
This study isn't very well-designed because it doesn't follow a strict plan to find and check all the important research. It might miss key studies or include biased ones, so we can't fully trust its conclusions — it's more like a summary than solid proof.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This is a narrative review that does not include primary data or systematic methods to establish causation. It summarizes existing literature but does not analyze study designs or control for confounding factors.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the provided text; the study appears to be an independent review based on existing guidelines and meta-analyses.
The article is a narrative review summarizing international guidelines and research, primarily authored by academics affiliated with academic institutions (e.g., Monash University). No industry ties, funding disclosures, or author affiliations with commercial entities are indicated. The absence of a COI or funding section limits certainty, but no evidence of bias or industry influence is present.
Key takeaways
- 01
1 in 8 pregnant women have PMOS; they are more likely to get gestational diabetes, high blood pressure, preterm birth, or have babies with low weight.
- 02
Yes — these complications can be serious for both mom and baby, and extra monitoring can help prevent them.
Surprising findings
- PMOS is now recognized as an independent risk factor for pregnancy complications—even after accounting for obesity.Many assumed obesity was the main driver of complications, but this review shows PMOS's metabolic dysfunction independently increases risk, meaning even lean women with PMOS are at elevated risk.
- The condition was renamed from PCOS to PMOS to reflect its systemic metabolic nature—not just ovarian.Most people still call it PCOS, but the study reveals the medical community is shifting terminology to emphasize it's a whole-body metabolic disorder, not just a reproductive one.
Practical takeaways
If you have PCOS/PMOS and are pregnant or planning pregnancy, ask your OB-GYN for a glucose tolerance test and blood pressure monitoring at every visit.
PMOS diagnosis isn't standardized yet, and many providers still use outdated PCOS criteria—so advocate for yourself with the term 'PMOS' and mention the 2023 guidelines.
high confidenceIf you're trying to conceive with PMOS, aim for a healthy pre-pregnancy weight and avoid excessive weight gain during pregnancy to reduce complication risks.
Weight loss during pregnancy is not recommended—focus on healthy weight maintenance and nutrition, not restriction.
medium confidenceWhy this study matters
PMOS Affects 1 in 8 Pregnant Women
Polyendocrine metabolic ovarian syndrome (PMOS) affects 10–13% of women globally—roughly 17 million pregnancies per year. These women face significantly higher risks of gestational diabetes, pre-eclampsia, preterm birth, and low birth weight due to insulin and hormone imbalances.
Most people think of PCOS as just a fertility issue, but this shows it’s a major pregnancy risk factor affecting millions—yet still ignored in routine prenatal care.
Weight Gain Isn't Just Lifestyle—It's Biological
Pre-pregnancy obesity and excessive gestational weight gain don't just add risk—they amplify PMOS's underlying metabolic dysfunction, making complications like diabetes and preeclampsia far more likely.
This flips the blame narrative: it's not that women 'eat too much'—it's that their biology makes weight gain a symptom of disease, not a choice.
Guidelines Changed in 2023—But Doctors Haven't Caught Up
Despite robust evidence from meta-analyses, the 2023 international guidelines now classify PMOS as a 'higher-risk' pregnancy condition—but most clinics still don't screen or adjust care accordingly.
A major medical shift happened, yet it's invisible to patients. This is a classic case of research-to-practice lag with real health consequences.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some women have a condition called PMOS that makes their bodies handle sugar and hormones differently, which can cause problems during pregnancy.
Research results
1 in 8 pregnant women have PMOS; they are more likely to get gestational diabetes, high blood pressure, preterm birth, or have babies with low weight.
What this means - more context
Yes — these complications can be serious for both mom and baby, and extra monitoring can help prevent them.
This narrative review examines the pathophysiology of polyendocrine metabolic ovarian syndrome (PMOS) during pregnancy and its association with adverse pregnancy outcomes, emphasizing the need for updated clinical recognition and management.
PMOS, affecting 10–13% of women globally, is linked to hyperinsulinaemia and hyperandrogenism, which interact with pregnancy physiology to increase risks of gestational diabetes, pre-eclampsia, preterm birth, and low birth weight. These risks are worsened by pre-pregnancy obesity and excessive gestational weight gain. Despite robust evidence, PMOS is under-recognized in antenatal guidelines, though the 2023 international guidelines now classify affected individuals as 'higher-risk'.
Methods Used
This is a narrative review synthesizing existing evidence from meta-analyses, clinical studies, and international guidelines; no primary data collection or statistical pooling was performed.
Main Finding
PMOS is a significant independent risk factor for multiple adverse pregnancy outcomes due to underlying metabolic and endocrine dysfunction, and current clinical guidelines now recommend classifying pregnant individuals with PMOS as 'higher-risk' to improve screening and management.
Confidence Level
High for clinical recommendations based on supporting meta-analyses; moderate for mechanistic claims due to reliance on observational and correlational evidence.
Study Flags
Red Flags
- •No primary data collection
- •No statistical effect sizes reported
- •Relies on aggregated findings from heterogeneous primary studies
Surprising Findings
PMOS is now recognized as an independent risk factor for pregnancy complications—even after accounting for obesity.
Many assumed obesity was the main driver of complications, but this review shows PMOS's metabolic dysfunction independently increases risk, meaning even lean women with PMOS are at elevated risk.
Practical Takeaways
If you have PCOS/PMOS and are pregnant or planning pregnancy, ask your OB-GYN for a glucose tolerance test and blood pressure monitoring at every visit.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This article is like a story that pulls together other people's research about a health condition, but it doesn't do any new experiments or check how good those other studies were. So it can tell you what people think might be linked, but it can't prove that one thing causes another.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Provides a comprehensive overview of current clinical understanding
- Cites recent guidelines (2023) and emerging research
- Highlights gaps in clinical practice and research priorities
Weaknesses
- Not a systematic review — lacks protocol, search strategy, or inclusion/exclusion criteria
- No assessment of risk of bias in included studies
- No quantitative synthesis or meta-analysis
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some women have a condition called PMOS that makes their bodies handle sugar and hormones differently, which can cause problems during pregnancy.
Research results
1 in 8 pregnant women have PMOS; they are more likely to get gestational diabetes, high blood pressure, preterm birth, or have babies with low weight.
What this means - more context
Yes — these complications can be serious for both mom and baby, and extra monitoring can help prevent them.
This narrative review examines the pathophysiology of polyendocrine metabolic ovarian syndrome (PMOS) during pregnancy and its association with adverse pregnancy outcomes, emphasizing the need for updated clinical recognition and management.
PMOS, affecting 10–13% of women globally, is linked to hyperinsulinaemia and hyperandrogenism, which interact with pregnancy physiology to increase risks of gestational diabetes, pre-eclampsia, preterm birth, and low birth weight. These risks are worsened by pre-pregnancy obesity and excessive gestational weight gain. Despite robust evidence, PMOS is under-recognized in antenatal guidelines, though the 2023 international guidelines now classify affected individuals as 'higher-risk'.
Methods Used
This is a narrative review synthesizing existing evidence from meta-analyses, clinical studies, and international guidelines; no primary data collection or statistical pooling was performed.
Main Finding
PMOS is a significant independent risk factor for multiple adverse pregnancy outcomes due to underlying metabolic and endocrine dysfunction, and current clinical guidelines now recommend classifying pregnant individuals with PMOS as 'higher-risk' to improve screening and management.
Confidence Level
High for clinical recommendations based on supporting meta-analyses; moderate for mechanistic claims due to reliance on observational and correlational evidence.
Study Flags
Red Flags
- •No primary data collection
- •No statistical effect sizes reported
- •Relies on aggregated findings from heterogeneous primary studies
Surprising Findings
PMOS is now recognized as an independent risk factor for pregnancy complications—even after accounting for obesity.
Many assumed obesity was the main driver of complications, but this review shows PMOS's metabolic dysfunction independently increases risk, meaning even lean women with PMOS are at elevated risk.
Practical Takeaways
If you have PCOS/PMOS and are pregnant or planning pregnancy, ask your OB-GYN for a glucose tolerance test and blood pressure monitoring at every visit.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This article is like a story that pulls together other people's research about a health condition, but it doesn't do any new experiments or check how good those other studies were. So it can tell you what people think might be linked, but it can't prove that one thing causes another.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Provides a comprehensive overview of current clinical understanding
- Cites recent guidelines (2023) and emerging research
- Highlights gaps in clinical practice and research priorities
Weaknesses
- Not a systematic review — lacks protocol, search strategy, or inclusion/exclusion criteria
- No assessment of risk of bias in included studies
- No quantitative synthesis or meta-analysis
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study isn't very well-designed because it doesn't follow a strict plan to find and check all the important research. It might miss key studies or include biased ones, so we can't fully trust its conclusions — it's more like a summary than solid proof.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This is a narrative review that does not include primary data or systematic methods to establish causation. It summarizes existing literature but does not analyze study designs or control for confounding factors.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the provided text; the study appears to be an independent review based on existing guidelines and meta-analyses.
The article is a narrative review summarizing international guidelines and research, primarily authored by academics affiliated with academic institutions (e.g., Monash University). No industry ties, funding disclosures, or author affiliations with commercial entities are indicated. The absence of a COI or funding section limits certainty, but no evidence of bias or industry influence is present.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
6 researchersIf this is your work, this is how we attribute it on Fit Body Science. Helena Jane Teede is listed as the lead author.